Although CSF3 therapy is the mainstay in the treatment of SCN patients to alleviate severe neutropenia and to prevent infection-related mortality and morbidity, contra-indications include poor neutrophil recovery, even when high dosages are given on a daily basis, and the risk of malignant transformation in some genetic subtypes of SCN. Here, CSF3 is linked to severe congenital neutropenia.